Hyperlipidemia Therapy TERCET Zabrze Registry
Launched by SILESIAN CENTRE FOR HEART DISEASES · Feb 22, 2017
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Hyperlipidemia Therapy TERCET Zabrze Registry is a clinical trial designed to study the effectiveness of treatments aimed at lowering cholesterol levels in patients who have high cholesterol and are at risk for heart problems. The researchers want to see if these treatments can help patients reach specific cholesterol goals after one year. For instance, they will check if patients with very high risk can lower their LDL cholesterol (often called "bad" cholesterol) to less than 70 mg/dL, and if those at high risk can lower it to less than 100 mg/dL. The study will also look at how well these treatments work over the years and how they relate to the severity of heart artery issues.
To be eligible for this trial, patients must have coronary artery disease along with high cholesterol. Unfortunately, those without coronary artery disease cannot participate. If you join the study, you will be monitored over time to see how well the lipid-lowering therapies work for you. This trial is currently recruiting participants of all genders, aged 65 and older. By participating, you could help researchers understand better ways to manage cholesterol and improve heart health for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients with coronary artery disease with hyperlipidemia
- Exclusion Criteria:
- • No coronary artery disease
About Silesian Centre For Heart Diseases
The Silesian Centre for Heart Diseases is a leading clinical research institution dedicated to advancing cardiovascular medicine through innovative research and clinical trials. With a strong commitment to improving patient outcomes, the Centre focuses on the development and evaluation of novel therapies and interventions for heart diseases. Its multidisciplinary team of experienced clinicians and researchers collaborates with national and international partners to ensure the highest standards of scientific rigor and ethical conduct in all studies. By prioritizing patient safety and efficacy, the Silesian Centre for Heart Diseases aims to contribute significantly to the field of cardiology and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zabrze, Upper Silesia, Poland
Patients applied
Trial Officials
Mariusz Gasior, prof.MD,PhD
Principal Investigator
3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials